摘要
创新能力的提升是生物医药行业创新升级的关键所在。从创新投入指标和创新产出指标两方面分析生物医药行业上市公司的创新绩效,构建符合生物医药上市公司创新绩效的评价指标体系。通过运用因子分析法对我国的生物医药上市公司2017—2021年的相关数据进行实证分析。结果表明:生物医药上市公司的创新绩效评价指标体系应该包括创新投入指标、创新产出指标和创新经济效益指标;生物医药上市公司的创新绩效整体呈现出良好的态势,而且具有明显的区域性。基于研究结论,提出有关优化我国生物医药上市公司创新发展的针对性建议。
Enhancing innovation capability has become a key factor in driving the upgrading of the biopharmaceutical industry.To analyze the innovation performance of listed companies in the biopharmaceutical industry,from the perspectives of innovation input indicators and innovation output indicators.It is constructed an innovation performance evaluation index system tailored to this field.Utilizes factor analysis to empirically analyze data related to biopharmaceutical listed companies in of China from 2017 to 2021.The research results that the innovation performance evaluation index system for biopharmaceutical listed companies should include,namely,innovation input indicators,innovation output indicators,and innovation economic benefit indicators.The overall innovation performance of biopharmaceutical listed companies presents a favorable trend and exhibits significant regional.Based on these findings,specific recommendations are put forward to optimize the innovation deve-lopment of biopharmaceutical listed companies in China.
作者
陈丽霞
王辰
CHEN Lixia;WANG Chen(School of Economics and Management,Changchun University of Science and Technology,Changchun 130022,China)
出处
《科技和产业》
2024年第1期68-75,共8页
Science Technology and Industry
关键词
生物医药
创新绩效
因子分析
biopharmaceutical
innovation performance
factor analysis
